LKQ Corporation vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nashville alternative auto parts distributor (NASDAQ: LKQ) ~$14B revenue; largest recycled/aftermarket parts provider, Pick Your Part sold Sept 2025 for $118M, Uni-Select integration competing with Copart and OEM dealers.
About
LKQ Corporation is a Nashville, Tennessee-based distributor of alternative and specialty automotive parts and accessories — publicly traded on NASDAQ (NASDAQ: LKQ) as an S&P 500 Consumer Discretionary component — operating as the largest provider of recycled, remanufactured, refurbished, and aftermarket vehicle parts and accessories across North America and Europe through approximately 45,000 employees and 1,700+ locations in 28 countries. LKQ serves collision repairers, mechanical repair shops, auto dealers, and retail consumers with alternative auto parts that are priced 25-50% below OEM dealer prices while meeting insurance company repair standards. In 2024, LKQ generated approximately $14 billion in revenue across its three operating segments: North America (wholesale recycled and aftermarket parts to US collision shops), Europe (acquired Uni-Select 2023 and operating as Rhiag/ECP for European aftermarket parts), and Specialty (truck and SUV accessories). A defining 2025 strategic action was the September 30, 2025 completion of the sale of the Self Service segment ("Pick Your Part" consumer self-service salvage yards) for $118 million — a divestiture that sharpens LKQ's focus on wholesale and specialty operations. CEO Justin Jude, who assumed leadership in 2023, has led the portfolio rationalization strategy.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.